Home Newsfeeds Exane BNP Paribas Initiates Coverage On McCormick & Co with Outperform Rating, Announces Price Target of $94

Exane BNP Paribas Initiates Coverage On McCormick & Co with Outperform Rating, Announces Price Target of $94

Exane BNP Paribas analyst Max Gumport initiates coverage on McCormick & Co (NYSE:MKC) with a Outperform rating and announces Price Target of $94.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Exane BNP Paribas analyst Max Gumport initiates coverage on McCormick & Co (NYSE:MKC) with a Outperform rating and announces Price Target of $94.

Tiziana Life Sciences Plans To Submit IND For Phase 1 Trial Of Intranasal Foralumab In Alzheimer’s Disease Patients

By Bill Haddad

October 12, 7:02 AM

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announcedTiziana Life Sciences Ltd.

TLSA

IPOs
News

Reported Earlier, Serve Robotics Prices $40M Public Offering Of 10M Common Shares At $4/Share And Up Lists To Nasdaq Capital Market

By Benzinga Newsdesk

April 18, 3:59 AM

Serve Robotics Inc. (the "Company" or "Serve"), a leading autonomous sidewalk delivery company, today announced the pricing of its underwritten public offering of 10,000,000 shares of common

SBOT